Derek M. D. Raghavan
#145,898
Most Influential Person Now
Derek M. D. Raghavan's AcademicInfluence.com Rankings
Derek M. D. Raghavanmedical Degrees
Medical
#2752
World Rank
#3185
Historical Rank
Oncology
#177
World Rank
#183
Historical Rank
Download Badge
Medical
Why Is Derek M. D. Raghavan Influential?
(Suggest an Edit or Addition)Derek M. D. Raghavan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (2004) (3631)
- Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. (2001) (3163)
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. (2003) (2206)
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (2008) (1744)
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015) (722)
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1992) (710)
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. (2009) (579)
- International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. (2011) (528)
- American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. (2012) (508)
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1997) (486)
- Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. (2016) (435)
- Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (429)
- Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. (2012) (423)
- Biology and management of bladder cancer. (1990) (418)
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. (1997) (332)
- Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. (2006) (290)
- Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment (2009) (279)
- Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (277)
- Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. (2000) (242)
- Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. (2014) (211)
- Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. (2011) (206)
- Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. (1986) (199)
- Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. (1991) (172)
- Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy (2010) (169)
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers (2018) (144)
- Antiandrogen withdrawal in castrate‐refractory prostate cancer (2008) (140)
- Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies. (1981) (134)
- Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (126)
- Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
- Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. (1988) (125)
- American Society of Clinical Oncology 2013 top five list in oncology. (2013) (122)
- American society of clinical oncology policy statement: disparities in cancer care. (2009) (119)
- The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. (1993) (117)
- Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (113)
- The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. (2013) (110)
- Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (108)
- Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. (1987) (102)
- The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. (1994) (100)
- Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. (2018) (100)
- Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. (1997) (96)
- Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. (1990) (89)
- Hypercholesterolemia after chemotherapy for testis cancer. (1992) (87)
- A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. (1989) (85)
- Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. (2017) (82)
- VP-16-213 (etoposide): the mandrake root from Issyk-Kul. (1982) (82)
- Phase II trial of carboplatin in the management of malignant mesothelioma. (1990) (79)
- Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
- Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines (2012) (78)
- Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors. (1981) (78)
- Bladder cancer xenografts: a model of tumor cell heterogeneity. (1986) (76)
- Survival disparities by Medicaid status (2012) (73)
- Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? (1991) (73)
- Textbook of Uncommon Cancer (2012) (71)
- Toxicity of treatment of germ cell tumors. (1992) (71)
- A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer (2004) (70)
- Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. (1987) (68)
- A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. (1988) (65)
- Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer? (1985) (64)
- Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined. (1988) (62)
- Translational studies of glutathione in bladder cancer cell lines and human specimens. (1997) (61)
- The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. (1988) (61)
- Oral cyclophosphamide for the management of hormone-refractory prostate cancer. (1993) (61)
- Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration. (1995) (61)
- Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. (1994) (60)
- Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
- Monoclonal antibodies to detect human tumours: an experimental approach. (1981) (55)
- The Oncologist® (54)
- Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. (2008) (54)
- Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation (1988) (53)
- Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. (1990) (52)
- Natural history of surgically treated bladder carcinoma with extravesical tumor extension (2003) (52)
- Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis. (1982) (50)
- Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy (2004) (49)
- Molecular targeting and pharmacogenomics in the management of advanced bladder cancer (2003) (47)
- Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. (2009) (46)
- Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma (1987) (46)
- Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties (2008) (46)
- Mediastinal nonseminomatous germ cell tumors: the role of combined modality therapy. (1982) (45)
- Elevated serum alphafetoprotein and seminoma clinical evidence for a histologic continuum? (1982) (44)
- Surgery and adjunctive chemotherapy for invasive bladder cancer. (2002) (42)
- Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines (2009) (42)
- Intravenous cis‐platinum for invasive bladder cancer (1984) (41)
- Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies (2006) (37)
- Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. (1986) (37)
- Management of bladder cancer. (1995) (36)
- Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. (1987) (35)
- MVAC for bladder cancer: time to move forward again. (1993) (35)
- Pre-emptive (Neo-adjuvant) Intravenous Chemotherapy for Invasive Bladder Cancer (1988) (34)
- Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. (1984) (34)
- Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. (1997) (33)
- Tumor classification and size in germ‐cell testicular cancer. Influence on the occurrence of metastases (1982) (33)
- Chemotherapy for hormone‐refractory prostate cancer: Beauty is in the eye of the beholder (2000) (33)
- Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. (2003) (32)
- Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". (1990) (32)
- Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. (2017) (32)
- Establishing Prostate Cancer Patient Derived Xenografts: Lessons Learned From Older Studies (2015) (31)
- Progress in the chemotherapy of metastatic cancer of the urinary tract (2003) (31)
- Testicular cancer: maintaining the high cure rate. (2003) (31)
- Hypothesis: when is a seminoma not a seminoma? (1981) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. (1989) (30)
- Spinal cord compression in prostate cancer. A 10-year experience. (1992) (29)
- A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors (1997) (29)
- Phase II study of megestrol acetate for metastatic carcinoma of the prostate. (1987) (29)
- Pre-emptive (neo-adjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer: age itself is not a contra-indication. (1988) (28)
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. (2000) (27)
- Multiple atypical nevi: a cutaneous marker of germ cell tumors. (1994) (27)
- The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. (1980) (27)
- Clinical staging of prostate cancer: Reproducibility and clarification of issues (2001) (27)
- Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. (2019) (26)
- Intracellular glutathione and cytotoxicity of platinum complexes (2004) (26)
- Aminoglutethimide in advanced prostatic carcinoma. (1987) (26)
- The impact of histological review on clinical management of testicular cancer. (1993) (26)
- Characterization of cell lines derived from a multiply aneuploid human bladder transitional‐cell carcinoma, UCRU‐BL‐13 (1989) (25)
- Innovations in the systemic therapy of prostate cancer (2010) (25)
- Metastatic bladder cancer: advances in treatment. (1997) (25)
- Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. (1988) (24)
- Initial Results from Mobile Low‐Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations (2019) (24)
- Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. (2005) (23)
- Site‐specific growth of the prostate xenograft line UCRU‐PR‐2 (1989) (23)
- Principles and practice of genitourinary oncology (1997) (22)
- Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC). (2009) (22)
- Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC) (2007) (22)
- Benign prostatic hyperplasia--video image analysis and its relationship to androgen and epidermal growth factor receptor expression. (1991) (21)
- Response criteria phase II/phase III invasive bladder cancer. (1986) (21)
- Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder. (1991) (20)
- Nanoparticles for delivery of chemotherapeutic agents to tumors. (2007) (20)
- Quality of life assessment in bladder cancer clinical trials: conceptual, methodological and practical issues. (1986) (20)
- Elastase activities of human bladder cancer cell lines derived from high grade invasive tumours. (1989) (20)
- Neoplastic venous involvement and pulmonary embolism in patients with germ cell tumors (1991) (20)
- Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group. (1990) (20)
- Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. (1983) (19)
- Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. (2004) (19)
- Management of hormone-resistant prostate cancer: an Australian trial. (1996) (19)
- Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. (1987) (19)
- Adjuvant chemotherapy for bladder cancer-why does level 1 evidence not support it? (2014) (19)
- Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). (1992) (18)
- Characterization of tumor mutation load (TML) in solid tumors. (2017) (18)
- Tumour‐induced host stromal‐cell transformation: Induction of mouse spindle‐cell fibrosarcoma not mediated by gene transfer (1990) (18)
- Experimental models of bladder cancer: a critical review. (1986) (18)
- Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years? (2014) (17)
- Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients. (1981) (17)
- Progress in the management of metastatic bladder cancer. (2000) (17)
- Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens. (1991) (17)
- Advanced breast cancer: response to high dose oral medroxyprogesterone acetate. (1984) (17)
- Deletion of Bleomycin From Therapy for Good Prognosis Advanced Testicular Cancer - a Prospective Randomized Study (1986) (17)
- Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly. (1992) (16)
- Disparities in cancer care: challenges and solutions. (2007) (16)
- Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. (2012) (16)
- Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats (1991) (16)
- Gender‐specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus (2014) (16)
- Molecular biology of urological tumours. (1990) (16)
- Management of advanced bladder cancer in the elderly. (1992) (16)
- Management changes for patients with endocrine-related cancers in the COVID-19 pandemic. (2020) (16)
- Preemptive (neoadjuvant) chemotherapy: can analysis of eligibility criteria, prognostic factors, and tumor staging from different trials provide valid or useful comparisons? (1990) (15)
- Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. (1987) (15)
- Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers (2022) (15)
- Personalizing medicine for cancer: the next decade (2010) (15)
- Complications of surgery and chemotherapy for testicular cancer. (2005) (15)
- StarClose Vascular Closure Device: Safety and Efficacy of Deployment and Reaccess in a Neurointerventional Radiology Service (2010) (15)
- Surveillance for Stage I Non-Seminomatous Germ Cell Tumours of the Testis: The Optimal Protocol has not yet been Defined (1989) (14)
- Chemotherapy of Advanced Colorectal Cancer A Randomized Trial of Sequential Methotrexate and 5‐Fluorouracil (1987) (14)
- Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. (1997) (14)
- Southwest Oncology Group studies in bladder cancer (2003) (14)
- A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer (2013) (13)
- Advanced bladder and urothelial cancers. (2000) (13)
- Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone. (1987) (13)
- Keynote address: a critical assessment of trials of neoadjuvant (preemptive) chemotherapy for bladder cancer: lesson for future studies of combined modality treatment. (1991) (13)
- Characterization of a new human bladder cancer cell line, UCRU-BL-28. (1993) (13)
- Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease (2011) (13)
- Small cell bladder cancer: biology and management. (2012) (12)
- Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy (1983) (12)
- Update in the management of prostate cancer (1990) (12)
- Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing (1992) (12)
- Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? (2011) (12)
- First-line intravenous cisplatin for deeply invasive bladder cancer: update on 70 cases. (1985) (11)
- Carboplatin for small cell lung cancer: progress toward greater efficacy and reduced toxicity. (1994) (11)
- Reported family history of cancer in 1,271 prostate cancer cases and 1,909 controls. (1995) (11)
- Chemotherapy for advanced bladder cancer: 'Midsummer Night's Dream' or 'Much Ado About Nothing'? (1990) (11)
- Cancer in the elderly population: the protection racket. (2006) (11)
- Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy (2008) (11)
- The clinical development of paclitaxel and the paclitaxel/carboplatin combination. (1998) (10)
- Long-term side effects after treatment of testicular cancer. (1990) (10)
- Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors. (2018) (10)
- The use of monoclonal antibodies for the diagnosis and therapy of bladder cancer. (1993) (9)
- Levine Cancer Institute Approach to Pandemic Care of Patients With Cancer. (2020) (9)
- Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: Evidence of a common histogenesis? (2004) (9)
- 1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study (1995) (9)
- Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients. (2016) (9)
- Clinical Trials in Genitourinary Oncology: What Have They Achieved? (1989) (9)
- Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet! (2004) (9)
- Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer. (1988) (9)
- Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): Final results. (2013) (9)
- Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. (1996) (9)
- Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030) (2013) (9)
- Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years (2015) (8)
- Prostate cancer: moving forward by reinventing the wheel...but this time it is round. (2008) (8)
- Dose intensity and outcome with combination chemotherapy for germ cell carcinoma. Australasian Germ Cell Trial Group. (1989) (8)
- Neoadjuvant chemotherapy of stage III‐A and B lung carcinoma using the pacco regimen (1995) (8)
- Assessment of quality of life in long-term survivors treated by first-line intravenous cisplatin for invasive bladder cancer. (1988) (8)
- Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response (2007) (8)
- Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen (2004) (8)
- The role of hepatitis B virus in the etiology of hepatocellular carcinoma in Australia. (1983) (7)
- Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. (1992) (7)
- Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma (2021) (7)
- Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC) (2004) (7)
- Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. (1995) (7)
- Experimental germ-cell tumors. (1980) (7)
- Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging Problem (2021) (7)
- Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder. (1988) (7)
- Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates (2004) (7)
- Cutaneous manifestations of genitourinary malignancy. (2016) (6)
- Neoadjuvant chemotherapy for invasive bladder cancer (2005) (6)
- Adjuvant systemic therapy of prostate cancer. (1995) (6)
- Systems pathology and predicting outcome after radical prostatectomy. (2008) (6)
- An Essay on Rearranging the Deck Chairs: What's Wrong with the Cancer Trials System? (2006) (6)
- Quantum leaps in treatment of high-risk breast cancer? Prove it! (1993) (6)
- Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (6)
- Invasive bladder cancer: ignoring the data. (2013) (6)
- Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low. (2018) (6)
- Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. (1993) (6)
- Hidden by HIPAA: the costs of cure. (2005) (6)
- Salvage or savage chemotherapy for poor-risk or relapsed testis cancer--20 years later, not much has changed. (2012) (5)
- Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: analysis in a preclinical survival model. (1996) (5)
- Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. (1986) (5)
- High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. (2019) (5)
- Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: a decade of experience. (1990) (5)
- Treatment of refractory testis cancer: salvage or savage chemotherapy? (1991) (5)
- Mediastinal seminomas (1980) (5)
- A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen. (1993) (5)
- Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer (2004) (5)
- Prostate cancer: too much dogma, not enough data. (2008) (5)
- 'Active surveillance' for stage I testis cancer: attaining maturity at 21 years. (2000) (5)
- ‘Active surveillance’ for stage I testis cancer (2000) (5)
- Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. (1987) (5)
- Slow progress in cancer care disparities: HIPAA, PPACA, and CHEWBACCA... but we're still not there! (2011) (5)
- Perioperative chemotherapy for invasive bladder cancer--what should we tell our patients? (1996) (5)
- Introduction: bladder cancer. (2012) (5)
- A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion (2004) (4)
- Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network (2021) (4)
- Karyotypic analysis of a heterogeneous human transitional cell carcinoma of the bladder. (1994) (4)
- Textbook of Uncommon Cancer, Third Edition (2006) (4)
- Neoadjuvant and classic adjuvant chemotherapy for bladder cancer (1991) (4)
- Genitourinary cancer in the elderly. (2004) (4)
- Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO? (2012) (4)
- Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting (2004) (4)
- Outcomes of a structured education intervention for Latinas concerning breast cancer and mammography (2017) (4)
- Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC). (2019) (4)
- Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed (2019) (4)
- Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” (1984) (4)
- Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. (1997) (4)
- Value in Oncology: Balance Between Quality and Cost. (2016) (4)
- Progress in the treatment of invasive bladder cancer (1996) (4)
- PSA: Please Stop Agonizing (over prostate-specific antigen interpretation). (2013) (4)
- Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs). (2019) (3)
- Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. (2010) (3)
- Chemotherapy for small cell lung cancer: induction and reinduction with VOCA. (1987) (3)
- The applications of xenografts in the study of human germ cell tumours. (1981) (3)
- Phase II clinical trial of recombinant alpha-2 interferon for biopsy-proven metastatic or recurrent renal carcinoma. (1992) (3)
- Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice (2004) (3)
- Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion (2004) (3)
- Active and pro-plasminogen activator on the surface of human bladder cancer cells derived from a high grade invasive tumour. (1990) (3)
- Principles of Chemotherapy for Genitourinary Cancer (2015) (3)
- A structured approach to uncommon cancers: what should a clinician do? (2013) (3)
- Bladder Cancer: Optimal Application of Preclinical Models to Suitable Translational Questions (2010) (3)
- BIOLOGY AND MANAGEMENT OF BLADDER CANCER. REPLY (1991) (3)
- Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer. (1985) (3)
- Towards the earlier diagnosis of testicular cancer. (1990) (3)
- Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer (2009) (3)
- Danazol treatment of advanced prostate cancer: Clinical and hormonal effects (1987) (3)
- Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration–Resistant Prostate Cancer: Missing Parts in a Superb Study (2009) (3)
- Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer. (1999) (3)
- Increased late toxicity in 12-20 year survivors of germ cell tumors (GCT). (2006) (3)
- Genitourinary tumors, prostate (2012) (3)
- Patient Navigation Associated with Decreased 30-Day All-Cause Readmission (2016) (3)
- First-line use of novel hormonal agents in prostate cancer: a critical appraisal. (2018) (3)
- Prostate cancer management under scrutiny: one man's meta-analysis is another man's poisson. (1999) (3)
- Clinician surrogates and equipoise: an analogy to lawyers who represent themselves? (1991) (2)
- Phase I study of epirubicin given on a weekly schedule. (1987) (2)
- Characterization of a new human cell line derived from a xenografted embryonal carcinoma (1982) (2)
- Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem (2015) (2)
- Costs of cancer care: rhetoric, value, and steps forward. (2013) (2)
- A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer (1988) (2)
- Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort (2020) (2)
- Testis cancer: the way forward. (1990) (2)
- Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. (2010) (2)
- Epirubicin: A phase II study in recurrent small-cell lung cancer (2004) (2)
- Textbook of Uncommon Cancer: Fourth Edition (2012) (2)
- VARIABILITY IN SURGICAL QUALITY IN A RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY AND PELVIC LYMPHADENECTOMY (2009) (2)
- Cytarabine: an inactive drug for extensive-stage small cell lung cancer. (1986) (2)
- Combination chemotherapy with cisplatin, vindesine and mitomycin‐C for advanced, inoperable non‐small‐cell lung cancer (1992) (2)
- 12 month survival for oncology patients with versus without patient navigation. (2016) (2)
- Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early‐Onset Colorectal Cancer (2021) (2)
- Germ Cell Tumors (2003) (2)
- Re: Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. (2007) (2)
- Prostate cancer, populations, politicians and power. (1997) (2)
- Survival trends of men and women with metastatic clear cell renal cell carcinoma. (2021) (1)
- Chemotherapy for Bladder Cancer in the Elderly (1993) (1)
- New prognostic factors for stage I testicular cancer: but will they make it to broadway? (2003) (1)
- Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients. (2022) (1)
- Testis Cancer: The Forgotten Poster Child (2014) (1)
- Human bladder cancer grown as xenografts and in tissue culture as models of the biology and treatment of invasive bladder cancer. (1988) (1)
- Sequential active chemotherapy schema in castration-resistant prostate cancer. (2011) (1)
- Carboplatin and VP16-213 with radiotherapy (RT) as initial treatment for patients with small-cell lung-cancer (SCLC) (1987) (1)
- Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates. (2004) (1)
- Value in Oncology: Balance Between Quality and Cost. (2016) (1)
- Hormone Therapy for Prostate Cancer (2003) (1)
- 1715 CELL CYCLE REGULATORY PROTEIN ALTERATIONS IN A PROSPECTIVE STUDY OF PATIENTS WITH ORGAN-CONFINED BLADDER CANCER FOLLOWING RADICAL CYSTECTOMY (2010) (1)
- Controversies in the management of localized prostate cancer: after the rhetoric. (2009) (1)
- Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy (2008) (1)
- Novel therapies for advanced prostate cancer: have we have widened the goal posts too far? (2012) (1)
- Paclitaxel for small cell lung cancer (SCLC) (1997) (1)
- The Renaissance clinician: essential for the modern management of prostate cancer. (2005) (1)
- Progress in management of advanced prostate cancer--don't throw the baby out with the bath water. (1998) (1)
- Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer. (2018) (1)
- HER2 Overexpression Is Frequently Discordant Between Primary and Metastatic Urothelial Carcinoma and is Associated with Intratumoral HER2 Heterogeneity. (2020) (1)
- Bladder preservation in patients with bladder cancer--quality versus quantity of life? (1998) (1)
- Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer. (2016) (1)
- Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients (2021) (1)
- Neoadjuvant intravenous cisplatin for T2-4NxMo bladder cancer. (1988) (1)
- Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes. (2022) (1)
- Mobile low-dose computerized tomography (LDCT): Three-year follow up of solution for early diagnosis of lung cancer in under-served populations. (2021) (1)
- A Prospective Study of Cisplatin-Based Combination Chemotherapy in Advanced Germ Cell Malignancy: Role of Maintenance and Long-Term Follow-Up (1989) (1)
- Gemcitabine, Oxaliplatin, and Paclitaxel (GOT) on a 2-Weekly Schedule in Patients (PTS) with Refractory Germ Cell Carcinoma: A Phase II Study Conducted at the University of Southern California (2012) (1)
- The treatment of disseminated prostate cancer with estramustine. (1992) (1)
- Fundamentals of Cancer Treatment (2006) (1)
- POINT: Is Cystectomy Needed for Small-Cell Bladder Cancer? (2015) (1)
- Evolving perspectives of the role of novel agents in androgen-independent prostate cancer (2008) (1)
- Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer. (1992) (1)
- Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC). (2018) (1)
- Current status and controversies in the management of genito-urinary cancer. (1985) (1)
- Chemotherapy in the management of invasive and metastatic bladder cancer. (1988) (1)
- Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy (2008) (0)
- Poster Listing – Tuesday 17 November 2015 (2015) (0)
- Abstract C09: Socioeconomic disparities in hospital admission patterns following cancer-related ED visits in the United States (2016) (0)
- Impact Of Genomic Testing Billing Practices On Utilization In Academic Hybrid Oncology Practice (2017) (0)
- Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers. (2021) (0)
- Section 1 : General Principles of Care of Uncommon Cancers 1 A Structured Approach to Uncommon Cancers (2017) (0)
- Re: Bladder Preservation Multimodality Therapy as an Alternative to Radical Cystectomy for Treatment of Muscle Invasive Bladder Cancer (2011) (0)
- Randomised comparison ofprocedures forobtaining informed consentinclinical trials oftreatment for cancer (1986) (0)
- The impact of Granulocyte-Colony Stimulating Factor (G-CSF) and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on cancer therapy. In Accomplishements in Cancer Research 1989 Eds, General Motor Cancer Research Foundation, Philadelphia PAN, Lippincott, 1990, pp204-211. (1989) (0)
- Discordance of HER2 expression in distant metastatic tumors (MTs) versus primary tumors (PTs) in urothelial carcinoma (UC). (2020) (0)
- Biology and management of bladder cancer. (1991) (0)
- Cells, sieves, positive and negative attraction: but...slow progress in bladder cancer. (2013) (0)
- Should hormone treatment be started early in response to rising prostate-specific-antigen levels? (2007) (0)
- Abstract No. 166: CT-guided percutaneous microwave ablation of retroperitoneal tumors: Preliminary results (2011) (0)
- Oncology. Are Voltaire and Rousseau now wrong? (1996) (0)
- Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer. (2022) (0)
- Clinical problems in advanced bladder cancer. (2004) (0)
- Arrogance or Stupidity? Unsuccessful Approaches to COVID-19 in Western Society. (2021) (0)
- Survival in men older than 75 years with low- and intermediate-grade prostate cancer managed with watchful waiting with active surveillance (2015) (0)
- Neutron radiotherapy in South Africa: neutron radiotherapy: Abratt supported. (2012) (0)
- Thursday 19 November 2015 (2015) (0)
- Active surveillance for stage I non-seminomatous germ cell testis tumors: practice and pitfalls. (1990) (0)
- COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients (2023) (0)
- Managed care did not contribute to the development of curative treatment of germ cell tumors. (1998) (0)
- Comprar Urological Oncology | Nargund, Vinod | 9781846283871 | Springer (2007) (0)
- A Structured Approach to Uncommon Cancers (2017) (0)
- Discordance rate of PD-L1 expression between primary and metastatic lesions in urothelial carcinoma (UC). (2018) (0)
- Faculty Opinions recommendation of Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. (2008) (0)
- Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network (2021) (0)
- Reply to M. Moore et al (2010) (0)
- Academic Hybrid Cancer Centers: Here Today, Gone Tomorrow? (2023) (0)
- How many errors to kill a population (2020) (0)
- Management of invasive bladder cancer: Strategies of combined modality treatment (1997) (0)
- Spiraling Costs: Who Will Address the Role of Medicolegal Drivers? (2012) (0)
- Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity (2021) (0)
- Introduction: Perspectives in bladder cancer (2003) (0)
- Choosing Wisely: Where's the Beef? (2015) (0)
- First-Line Intravenous Cisplatin for Deeply Invasive Bladder Cancer: Update on 70 Cases (1986) (0)
- High incidence of concurrent disease states detected during mobile lung cancer screening in an underserved population. (2021) (0)
- RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE (1999) (0)
- Upper respiratory tract SARS-CoV-2 viral shedding in cancer patients. (2021) (0)
- Clinical pharmacology and cancer chemotherapy: an evolving interface? (1986) (0)
- Male Reproductive Function, Aging and Testosterone Replacement (2008) (0)
- Poster Listing – Wednesday 18 November 2015 (2015) (0)
- Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer (2022) (0)
- Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN). (2020) (0)
- Combined modality treatment of bladder cancer (1990) (0)
- POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. (2006) (0)
- Abstract PR006: Screening under-served populations by mobile low dose computerized tomography (LDCT) scans results in stage shift with potential cures: Time for a change in health policy? (2023) (0)
- Active surveillance for stage I testis cancer: two steps forward one step back. (1993) (0)
- No Bridge Over Troubled Water: Slow Progress in Bladder Cancer. (2017) (0)
- Are Voltaire and Rousseau now wrong? (1996) (0)
- Pathogenic variants in PTEN to predict for increased risk of relapse and death in patients with limited stage small cell bladder cancer. (2020) (0)
- Levine Cancer Institute Financial Toxicity Control Program: Expanding the program to reduce fiscal vulnerability of patients. (2022) (0)
- Sequential Androgen Deprivation and Chemotherapy in Metastatic Prostate Cancer: Discordant Responses in Pilot Study Suggest an Opportunity for Individualized Therapy (2012) (0)
- Chapter 4 – Principles of Chemotherapy for Genitourinary Cancer (2005) (0)
- Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer (2021) (0)
- Characterization of sociodemographic and clinicopathological features and associated outcomes of patients (Pts) with anal squamous cell cancer (ASCC): Analysis of 44,084 pts in the National Cancer Database (NCDB). (2020) (0)
- Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program (2016) (0)
- I. SUBJECT: NEW PRINCIPAL INVESTIGATORS (PI) AND CO-PI Recommendations have been made that the following physicians assume the responsibilities of Principal Investigators and Co-Principal Investigators at the following Member and CCOP Institutions: (2011) (0)
- Effectiveness of mobile computerized tomographic (CT) lung scanning unit for early diagnosis of lung cancer in under-served populations. (2019) (0)
- Seminar article Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder (2003) (0)
- Risk factors for hospitalization for cancer patients with SARS-CoV-2 infection. (2021) (0)
- Invasive Bladder Cancer: Combined Modality Treatment (2015) (0)
- Emerging strategies in the treatment of advanced bladder and urothelial cancers : in cooperation with the University of Southern California/Norris Comprehensive Cancer Center (2000) (0)
- Abstract A62: Survival outcomes in patients with curable cancers: Disparities by Medcaid status (2010) (0)
- Wheels Up: Bringing Lung Cancer Education and Screening to Rural Patients (2018) (0)
- Chemotherapy for invasive bladder cancer: facts and fallacies. (1990) (0)
- Deletion of Bleomycin From Therapy for Good Prognosis Advanced Nonseminomatous Germ-Cell Tumor of the Testis - a Prospective Randomized Study (1989) (0)
- In germ cell cancer, are we at the end of the chemotherapy era? No-targeted therapies have not heralded its demise. (2013) (0)
- Screwing up cancer care (2020) (0)
- EDITORIAL: MANAGED CARE DID NOT CONTRIBUTE TO THE DEVELOPMENT OF CURATIVE TREATMENT OF GERM CELL TUMORS (1998) (0)
- RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987 (2012) (0)
- Radiotherapy and chemotherapy for invasive bladder cancer. (1998) (0)
- Considerations in the Use of Neoadjuvant and Adjunctive Systemic Chemotherapy in Treatment of Invasive Bladder Cancer by Cystectomy (2001) (0)
- A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC). (2018) (0)
- Reply to L.k. Griffeth et al and J.E. Battley et al. (2014) (0)
- Remembering old lessons in prostate cancer: avoiding errors 'in PARPituity'. (2013) (0)
- Phase I I T rial o f G emcitabine P lus C isplatin i n P atients With M etastatic U rothelial C ancer (2000) (0)
- Testis cancer: on gilding the lily. (2013) (0)
- Value in Oncology: Beware Putting Lipstick on a Pig. (2020) (0)
- Yes, We Have No Bananas! (2010) (0)
- Socioeconomic status (SES) and survival outcomes in patients with gastrointestinal (GI) cancers: An analysis of 1.4 million patients in the National Cancer Database (NCDB). (2021) (0)
- Abstract B03: Identification of PTEN p.W274C as a potential biomarker to predict inferior survival in patients with limited-stage small-cell bladder cancer (2020) (0)
- Non-seminomatous testicular cancer, 1989: primum non nocere. (1989) (0)
- Testis cancer: on gilding the lily. (2013) (0)
- Balancing Outcomes: Focusing on Value in Treatment of Prostate Cancer. (2018) (0)
- Total androgen blockade for prostate cancer: the end does not justify the means. (1996) (0)
- Orbital metastasis from prostatic carcinoma. (1975) (0)
- Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer. (1990) (0)
- Functional heterogeneity of prostatic intra-epithelial neoplasia: Length of hormonal therapy influences response. (2016) (0)
- Wealth of Riches in RCC Treatment: How Do We Avoid 'Devaluing the Dollar'? (2007) (0)
- Tuesday 17 November 2015 (2015) (0)
- Systemic Therapy for Invasive Bladder Cancer: The Value Proposition (2016) (0)
- Novel Therapies in the Honeymoon Period (2006) (0)
- Faculty Opinions recommendation of Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. (2007) (0)
- Co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET is low in metastatic urothelial carcinoma. (2023) (0)
- American Society of Clinical Oncology 2013 Top Five List in (2013) (0)
- Survival of young black males with metastatic clear cell renal cell carcinoma. (2022) (0)
- Wednesday 18 November 2015 (2015) (0)
- Radical C ystectomy i n t he T reatment o f I nvasive B ladder Cancer: L ong-Term R esults i n 1 ,054 P atients (2001) (0)
- Should hormone treatment be started early in response to rising PSA levels (2007) (0)
- Predicting Low Trial Accrual Mathematically: Is That the Right Emphasis? (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Derek M. D. Raghavan?
Derek M. D. Raghavan is affiliated with the following schools:
